Sonidegib in Adult Patients with Locally Advanced Basal Cell Carcinoma (laBCC) in China

Phase 4

Active, not recruiting

• Conditions: Carcinoma, Basal Cell (BCC)
• Interventions: Drug: Sonidegib Phosphate Capsules

• Registration Number: NCT06880848
• Lead Sponsor: Jemincare

Brief Summary

This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation therapy, curative surgery or other local therapies.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-06-21
• Status Verified: 2025-03
• Study First Submitted: 2025-03-12
• Study First Submitted QC: 2025-03-12
• Last Update Submitted: 2025-03-12
• Study First Posted: 2025-03-18
• Last Update Posted: 2025-03-18
• Primary Completion: 2025-09
• Study Completion: 2025-09

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

1. Age 18 years or older.
2. Patients with a histologically confirmed diagnosis of laBCC that is not amenable to radiation therapy, curative surgery, or other local therapies. Patients with laBCC must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥ 10 mm, with MRI/CT scan or on color photographs.
3. ECOG PS Score ≤ 2.
4. Patients with adequate bone marrow, liver and renal function.
5. Written informed consent obtained prior to any screening procedures.
6. Patients are willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions.
7. Females of childbearing potential agree to use contraception during treatment and for 20 months following the last dose; male patients (even after vasectomy) agree to use contraception during treatment and for 8 months after the last dose.

Exclusion Criteria

1. Subjects in the opinion of the investigator are immunosuppressed (e.g., organ transplant recipients, HIV, systemic invasive malignancy within past 5 years excluding Stage I cervical cancer, ductal carcinoma in situ of the breast or CLL stage 0, graft vs. host disease, etc.).
2. LaBCC patients with skin lesions in multiple body locations will not be considered metastatic patients. LaBCC patients with positive (histological confirmation of BCC) regional nodal disease will be considered to have metastatic disease.
3. Poorly controlled diabetes mellitus (as per Investigator's discretion in consultation with Sponsor's medical monitor).
4. Major surgery within 4 weeks prior to study treatment.
5. Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data.
6. Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromes.
7. Patients who have previously been treated with systemic Sonidegib or with other Hh pathway inhibitors.
8. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy).
9. Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment.
10. Have participated in other clinical trials within 4 weeks prior to the first dose of sonidegib.
11. Have received other anti-neoplastic therapy within 4 weeks prior to study treatment.
12. Patients who are receiving medications known to be moderate and strong inhibitors or inducers of cytochrome P450 (CYP) 3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with sonidegib. Medications that are strong CYP3A4/5 inhibitors should be discontinued at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with sonidegib.
13. Pregnant or nursing (lactating) women, confirmed by a positive hCG laboratory test (> 5mIU/mL).
14. Unwilling or unable to comply with the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Sonidegib Phosphate Capsules	Sonidegib Phosphate Capsules	Participants will receive continuous treatment with oral administration once a day until conditions for treatment termination are met.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	up to 1 year	Objective response rate (ORR) is defined as the percentage of participants with a confirmed complete or partial response (CR or PR) , per modified Response Evaluation Criteria in Solid Tumors (mRECIST) as assessed by central review.

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DoR)	up to 1 year	The DOR for a responder is defined as the time from the participant's initial CR or PR to the first date of either disease progression or death, whichever occurs first. CR, PR and PD will be determined per mRECIST by investigator and central review, respectively
Complete response rate (CRR) per central and investigator review	up to 1 year	CRR is defined as the percentage of participants who achieved a complete response per mRECIST
Progression-free Survival (PFS)	up to 1 year	PFS is defined as the time from the participant's first dose of study treatment to the first date of either disease progression or death, whichever occurs first. Disease progression will be determined per mRECIST by investigator and central review, respectively
Time to tumor response (TTR)	up to 1 year	TTR is defined as the time from the participant's first dose of study treatment to the date of initial CR or PR. CR and PR will be determined per mRECIST by investigator and central review, respectively.
Adverse event (AE)/Serious adverse event (SAE)/Treatment emergent adverse event (TEAE)	up to 1 year	Adverse events, and changes from baseline in vital signs,etc

Trial Locations

Locations (1)

Peking University First Hospital; 🇨🇳 Beijing, China